Tenex (guanfacine) Disease Interactions
There are 4 disease interactions with Tenex (guanfacine):
Alpha-2 Agonists (Central) (Includes Tenex) ⇔ Bradyarrhythmia
Moderate Potential Hazard, High plausibility
Applies to: Heart Block, Sinus Node Dysfunction
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.
Alpha-2 Agonists (Central) (Includes Tenex) ⇔ Depression
Moderate Potential Hazard, Moderate plausibility
Applies to: Depression
Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.
Alpha-2 Agonists (Central) (Includes Tenex) ⇔ Hypotension
Moderate Potential Hazard, High plausibility
Applies to: Hypotension, Cerebrovascular Insufficiency, Ischemic Heart Disease, Peripheral Arterial Disease
Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.
Guanfacine (Includes Tenex) ⇔ Renal/Liver Disease
Moderate Potential Hazard, Low plausibility
Applies to: Liver Disease, Renal Dysfunction
Normally, approximately 50% of a guanfacine dose is eliminated unchanged by the kidney and the rest metabolized by the liver. However, neither the parent drug nor its metabolites accumulate significantly during chronic dosing in patients with severe renal impairment due to increased hepatic metabolism of the drug in these patients. Thus, initial dosage adjustments are generally not necessary in renal impairment. Dosage titration, however, should be made cautiously if hepatic function is also compromised. The pharmacokinetics of guanfacine has not been studied in patients with liver disease. The manufacturer recommends caution when the drug is used in such patients.
You should also know about...
Tenex (guanfacine) drug Interactions
There are 282 drug interactions with Tenex (guanfacine)
Tenex (guanfacine) food/lifestyle Interactions
There is 1 food/lifestyle interaction with Tenex (guanfacine)
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
